EMI (Encore Medical) Other Current Receivables: $0.00 Mil (As of Dec. 2025)


What is Encore Medical Other Current Receivables?

Encore Medical EMI Other Current Receivables is $0.00 Mil as of Dec. 2025.

Encore Medical's Other Current Receivables for the quarter that ended in Dec. 2025 was $0.00 Mil.

Encore Medical Other Current Receivables Related Terms

Encore Medical Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Encore Medical's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical Other Current Receivables Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
Other Current Receivables
0.00 0.00 0.00

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Other Current Receivables Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Encore Medical Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.00 Mil mean?
Encore Medical (EMI) has a Other Current Receivables of $0.00 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Encore Medical and its competitors.
Is Encore Medical's Other Current Receivables too high?
Encore Medical's current Other Current Receivables is $0.00 Mil.
How does Encore Medical's Other Current Receivables compare to ?
Encore Medical's Other Current Receivables of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Encore Medical and its competitors. Encore Medical's current Other Current Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Other Current Receivables of $0.00 Mil. The current Other Current Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Encore Medical (EMI), the current Other Current Receivables is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).